December 30, 2003

Skinvisible Announces Cancellation of Marketing Rights

LAS VEGAS, Dec 30, 2003 /PRNewswire-FirstCall via Comtex/ --

Skinvisible, Inc. (OTC Bulletin Board: SKVI) (Website: www.skinvisible.com ) through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc. had announced on July 9, 2003, that it had entered into a letter of intent with Health First Distributors North America, Inc. of British Columbia, Canada ('Health First') granting Health First the exclusive marketing and distribution rights to the antimicrobial hand sanitizer product identified as the Triclosan 1% formula (the 'Product'). On October 29, 2003, the parties revised the letter of intent.

Despite repeated assurances of payment from Health First, we have not received the second of the required non-refundable deposits in the amount of $100,000 USD that was due on November 30, 2003. As a result of Health First's failure to satisfy the conditions precedent to entering into a formalized License Agreement, we have terminated negotiations with Health First and will retain the $100,000 non-refundable deposit previously paid by Health First as provided in the Letter of Intent.

In addition, on October 15, 2003 we announced that we had reached an agreement with Edward Fitzpatrick and European Launch Pad ('ELP') to provide a full market research report on a minimum of 16 sub-licensees in different countries in Europe for our products, along with locating a master licensee for Europe and subsequent sub-licensees in the territory to market and sell our product formulations and proprietary 'Invisicare'polymers. We received notice from Mr. Fitzpatrick that he was terminating this agreement and will not provide any future services. We are negotiating with Mr. Fitzpatrick on the terms of the return of any shares of our common stock he has already received under the agreement.

Headquartered in Las Vegas, Nevada, Skinvisible, Inc. is focused on the development of innovative topical polymer-based delivery systems and related technologies incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymers into stable water emulsions. Skinvisible's primary marketing and sales objectives are to license its technologies and/or sell its delivery systems to provide enhanced product performance for established brand manufacturers and providers of prescription, over-the-counter, cosmetic, and skincare products. In addition Skinvisible formulates and manufactures products for private label customers.

This press release contains 'forward looking'statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934 as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports that will be on file with the US Securities and Exchange Commission (including but not limited to the report on Form 10-QSB for the quarter ending September 30, 2003).

For Info. Contact: T. Howlett - Skinvisible, Inc. - Ph. (702) 433-7154 / Fax (702) 433-7192 / Email: terry@skinvisible.com

Press Release Index

New Press Release Alerts:

If you are interested in receiving corporate and new product development news from Skinvisible, simply enter your email address below.